The Expression of ERCC1, RRM1, and BRCA1 in Breast Cancer According to the Immunohistochemical Phenotypes

被引：32
作者：
Kim, Dokyung [1 ]
Jung, Woohee [1 ]
Koo, Ja Seung [1 ]
机构：
[1] Yonsei Univ, Severance Hosp, Coll Med, Dept Pathol, Seoul 120752, South Korea
来源：
JOURNAL OF KOREAN MEDICAL SCIENCE | 2011年 / 26卷 / 03期
关键词：
Breast Neoplasms; ERCC1; RRM1; BRCA1; MESSENGER-RNA LEVELS; GENE-EXPRESSION; FLUOROURACIL CHEMOTHERAPY; PROGNOSTIC FACTORS; CISPLATIN; SURVIVAL; REPAIR; PROTEIN; OXALIPLATIN; MUTATIONS;
D O I：
10.3346/jkms.2011.26.3.352
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We studied the expression of BRCA1, ERCC1, and RRM1 which play an important role in DNA repair systems in breast cancer. Immunohistochemical staining for EGFR, BRCA1, ERCC1, and RRM1 were performed by using a tissue microarray made from 230 breast cancer patients. Patients were classified into luminal A, luminal B, HER-2, and triple negative breast cancer (TNBC) types according to ER, PR, and HER-2 expression. The expression of ERCC1, RRM1, and BRCA1 were correlated (P < 0.05). The expression level of ERCC1 was the lowest in TNBC type (P = 0.031), ERCC1 negativity was more prominent in TNBC and luminal B groups than luminal A and HER-2 groups (P = 0.013). Cases with EGFR overexpression showed high expression of RRM1 and BRCA1 (P = 0.046, and 0.004, respectively). In conclusion, the expression of ERCC1 is particularly lower in TNBCs than other types of breast cancers.
引用
收藏
页码：352 / 359
页数：8
相关论文
共 32 条
  • [1] High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
    Abd El-Rehim, DM
    Ball, G
    Pinder, SE
    Rakha, E
    Paish, C
    Robertson, JFR
    Macmillan, D
    Blamey, RW
    Ellis, IO
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (03) : 340 - 350
  • [2] BRCA1 gene expression in breast cancer:: A correlative study between real-time RT-PCR and immunohistochemistry
    Al-Mulla, F
    Abdulrahman, M
    Varadharaj, G
    Akhter, N
    Anim, JT
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2005, 53 (05) : 621 - 629
  • [3] Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer
    Bergamaschi, Anna
    Kim, Young H.
    Wang, Pei
    Sorlie, Therese
    Hernandez-Boussard, Tina
    Lonning, Per E.
    Tibshirani, Robert
    Borresen-Dale, Anne-Lise
    Pollack, Jonathan R.
    [J]. GENES CHROMOSOMES & CANCER, 2006, 45 (11) : 1033 - 1040
  • [4] The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin
    Bhattacharyya, A
    Ear, US
    Koller, BH
    Weichselbaum, RR
    Bishop, DK
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) : 23899 - 23903
  • [5] ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
    Ceppi, P.
    Volante, M.
    Novello, S.
    Rapa, I.
    Danenberg, K. D.
    Danenberg, P. V.
    Cambieri, A.
    Selvaggi, G.
    Saviozzi, S.
    Calogero, R.
    Papotti, M.
    Scagliotti, G. V.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (12) : 1818 - 1825
  • [6] BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer
    Couch, FJ
    DeShano, ML
    Blackwood, MA
    Calzone, K
    Stopfer, J
    Campeau, L
    Ganguly, A
    Rebbeck, T
    Weber, BL
    Jablon, L
    Cobleigh, MA
    Hoskins, K
    Garber, JE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (20) : 1409 - 1415
  • [7] CUTLER SJ, 1969, CANCER, V24, P653, DOI 10.1002/1097-0142(196910)24:4<653::AID-CNCR2820240402>3.0.CO
  • [8] 2-B
  • [9] PATHOLOGICAL PROGNOSTIC FACTORS IN BREAST-CANCER .1. THE VALUE OF HISTOLOGICAL GRADE IN BREAST-CANCER - EXPERIENCE FROM A LARGE STUDY WITH LONG-TERM FOLLOW-UP
    ELSTON, CW
    ELLIS, IO
    [J]. HISTOPATHOLOGY, 1991, 19 (05) : 403 - 410
  • [10] Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
    Farmer, H
    McCabe, N
    Lord, CJ
    Tutt, ANJ
    Johnson, DA
    Richardson, TB
    Santarosa, M
    Dillon, KJ
    Hickson, I
    Knights, C
    Martin, NMB
    Jackson, SP
    Smith, GCM
    Ashworth, A
    [J]. NATURE, 2005, 434 (7035) : 917 - 921
1234